对于家里经济条件一般的家庭长大的人来说，比如我，很多令人习以为常的 “常识” 是从二十多岁开始才知道的比如，牙齿不齐是需要去整牙的，脊柱侧弯是需要去矫正的，轻度的近视在青少年阶段用角膜塑形镜是可以很大程度延缓近视度数加深的身体健康的养护和矫正，都是只有在 18 岁以下的黄金时期效率最高。再比如多语言环境，人年纪越小学语言越容易,并且多语言环境能促进大脑发育哪怕现在已经在做这些矫正项目让自己更健康，开始学一些小语种，可能也是有点追求完美主义，偶尔深夜想到这些还是会有遗憾，碍于客观的条件没能在最正确的时候做最正确的事，到了一把年纪了才知道补救贫穷局限了视野和认知，但感谢过去的贫穷让人更知道机会可贵，错过好的 timing 是多么可惜的事。和投资一样，在正确的时间做正确的事，举例就是在 early stage 开始玩 sol meme，随便买什么，大多都去了 100M，而到了下行期才开始玩 sol meme 扫链，10M 都难 ...

Core Insights - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, with specific rates of 14.5% for 6-year-olds, 36% for elementary school students, 71.6% for middle school students, and 81% for high school students [2] Company Strategy - The company aims to raise awareness of its treatment plan to over 20 million people and ensure that over 1 million children receive timely and appropriate medication this year [2] - The company will implement a comprehensive multi-channel sales strategy, focusing on collaboration with retail channels and continuing academic promotion to build a network for myopia prevention and control [2]

Core Viewpoint - Mingyue Lens, a leading lens brand in China, collaborates with Qianye Glasses to launch a campus public welfare campaign aimed at promoting vision health among children and adolescents, addressing the rising myopia rates in the country [1][5][8] Group 1: Campaign Overview - The campaign titled "Climbing to the Peak and Building Dreams for a Voyage" involves sharing learning experiences and myopia prevention knowledge with students in Chongqing [1] - Tsinghua University student leader Zhang Zhiyuan participated in the event, providing practical study techniques and encouraging students to adopt healthy eye care practices [1][3] Group 2: Myopia Statistics and Importance - According to the National Health Commission, the overall myopia rate among children and adolescents in China is projected to reach 52.7% by 2024, indicating that one in two students is affected [5] - The significance of myopia prevention is underscored by the alarming statistics, prompting initiatives like the public welfare campaign [5] Group 3: Product Offering - Mingyue Lens offers the "Mingyue Easy Control Lens," designed specifically for Chinese children's eye habits, balancing prevention effectiveness and comfort [5] - Clinical trials conducted by Zhongshan Ophthalmic Center and Tianjin Eye Hospital show that the lens has a myopia progression control effectiveness rate of 73.82%, with results published in the international journal "Ophthalmology" [5] Group 4: Social Responsibility - As a national brand, Mingyue Lens emphasizes its social responsibility by promoting myopia prevention awareness across the country, advocating for the protection of children's vision as a means to secure a brighter future [8]

Core Viewpoint - The Ministry of Education, in collaboration with the National Health Commission and the National Disease Control Bureau, has issued a notification aimed at preventing myopia in children by promoting the preservation of hyperopia reserves through various measures [1][2]. Group 1: Policy Recommendations - The notification suggests comprehensive measures based on age groups, recommending that children aged 0-3 should avoid screens and ensure over 10 hours of sleep daily [1]. - For preschool children aged 3-6, outdoor play is emphasized, with a strong recommendation to limit screen time and avoid early academic pressure [1]. - Primary schools are advised to implement physical exercise plans that align with children's physical development, ensuring at least 2 hours of outdoor activity daily to foster good eye habits [1]. Group 2: Health Monitoring and Management - The notification mandates regular eye health checks, with medical institutions required to conduct refraction screenings to monitor children's hyperopia reserves [2]. - Primary schools must implement a bi-semester vision monitoring system to track students' vision and hyperopia reserve trends, providing timely feedback to parents [2]. - There is an emphasis on early detection of myopia risks, with recommendations for parents to seek professional evaluations for children showing abnormal vision indicators or insufficient hyperopia reserves [2].

Core Insights - The launch of the "National Vision Health Report (2026 Edition)" was officially initiated at the 8th China International Import Expo, led by Professor Li Ling from Peking University Health Development Research Center and supported by EssilorLuxottica [1][3] Group 1: Vision Health Report - The first edition of the "National Vision Health Report" was published in 2016, marking it as China's first systematic research white paper on vision health, which has since elevated myopia prevention to a national strategy [3][4] - The new version will deepen the focus on myopia prevention among youth and expand to "lifecycle vision health," leveraging successful experiences in myopia prevention to enhance system construction through policy and technology [3][4] Group 2: Collaboration and Initiatives - EssilorLuxottica announced support for the Shanghai Eye Disease Prevention and Treatment Center to launch the national health industry standard "Technical Guidelines for Graded and Classified Prevention and Treatment of Myopia in Children and Adolescents" [3][4] - Last year, EssilorLuxottica provided over 8,000 lenses to support a school-based myopia intervention project in Shanghai, which is part of the city's three-year action plan to strengthen public health systems [4]

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since entered a downward trend, with a cumulative decline of 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a peak of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend characterized by "nine consecutive declines" and "ten consecutive declines," resulting in a cumulative drop of 30% [1] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the following day [2][4] Group 2: Financial Performance - For the first half of 2023, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a year-on-year decline of 68.25%, and a net loss of HKD 117 million, an increase of 53.85% compared to the previous year [4] - The significant revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - After adjusting for this one-time income, the product revenue for the current period was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development and Market Potential - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop, has made significant progress, with its ANDA application accepted by the National Medical Products Administration of China [4][5] - The company is currently the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong competitive position [5] - The potential market for myopia control in China is substantial, with approximately 700 million myopic patients, including 163 million children and adolescents who could benefit from NVK002 [5] - According to estimates, the myopia prevention market could reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Sentiment and Future Outlook - Following a significant price increase, the stock has shown signs of consolidation, with a current PB ratio of 0.92, well below the industry average of 3.15 [3] - The stock has experienced a "price flat, volume shrinking" phenomenon, indicating a potential stabilization at lower price levels [15] - Recent trading activity suggests that the stock may be nearing a bottom, with a potential for upward momentum if trading volume increases [15]

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since declined by approximately 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a high of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend, experiencing a "slow knife" decline with a cumulative drop of 30% over two and a half months [1][2] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the next day [2][6] Group 2: Financial Performance - For the first half of 2025, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a decline of 68.25% year-on-year, and a net loss of HKD 117 million, widening by 53.85% [4] - The revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - Excluding this factor, product revenue was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop for myopia control, has made significant progress, with its ANDA application accepted by the National Medical Products Administration [4][5] - The company is the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong market position [5] - The global myopia control market is projected to reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Dynamics - The current PB valuation of Zhaoke Ophthalmology is 0.92, significantly lower than the industry average of 3.15, indicating potential undervaluation [3] - The market for low-concentration atropine eye drops is currently limited, with only one competitor, suggesting a favorable competitive landscape for NVK002 [5] - Recent trading patterns indicate a consolidation phase, with a significant portion of the stock's average cost now at HKD 3.24, suggesting improved control by major investors [12][15]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of 98.10 CNY for the next six months [5][7]. Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, achieving 1.904 billion CNY in revenue and 599 million CNY in net profit, representing year-on-year growth of 32.27% and 105.98%, respectively [2][5]. - The overall gross margin for the company in Q1-Q3 2025 was 81.33%, an increase of 2.94 percentage points compared to the previous year, driven by the strong sales of its core product, low-concentration atropine eye drops [2][4]. - The low-concentration atropine eye drops are recognized in multiple guidelines as a foundational medication for long-term management of myopia in children and adolescents, indicating a large market potential and favorable competitive landscape [3][4]. Financial Performance - The company is expected to achieve net profits of 803 million CNY, 1.021 billion CNY, and 1.241 billion CNY for the years 2025, 2026, and 2027, reflecting year-on-year growth rates of 137.6%, 27.1%, and 21.5%, respectively [5][11]. - The projected earnings per share (EPS) for 2025 is 3.27 CNY, with a price-to-earnings (PE) ratio of 30 times [5][11]. - The company’s revenue is forecasted to grow from 2.565 billion CNY in 2025 to 3.848 billion CNY in 2027, with a compound annual growth rate (CAGR) of 20% [11][12]. Research and Development - The company is actively expanding its research and development pipeline, covering various common ophthalmic diseases, with several products making progress in clinical trials [4][5]. - Notable advancements include the initiation of phase III clinical trials for lidocaine eye gel and the completion of phase II trials for voriconazole eye drops [4].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential stock price increase of over 15% relative to the benchmark index [4]. Core Insights - The company achieved a revenue of 227 million yuan in Q3 2025, representing a year-on-year growth of 14.59%. The net profit attributable to shareholders was 54 million yuan, up 11.56% year-on-year [1]. - The focus on core products has led to significant growth, with the PMC Ultra Bright series seeing a year-on-year increase of 53.7%. The three major star products accounted for 56.3% of the revenue from conventional lenses [1]. - The launch of the high-end "Tianji" series aligns with consumer needs in China and enhances the company's position in the high-end lens market [1]. - The "Easy Control" series, endorsed by Guo Jingjing, has strengthened brand recognition in the youth myopia prevention sector, establishing the company as a leading domestic brand [2]. - A strategic partnership with Aier Eye Hospital aims to explore innovative cooperation in various fields, enhancing the company's market presence [2]. - The collaboration with Xiaomi on AI glasses has generated 6.51 million yuan in revenue, with a gross margin of 78.6% for the smart glasses lenses [3]. - R&D investment has increased, with a R&D expense ratio of 5.85% in Q3 2025, reflecting a commitment to technological innovation [3]. Financial Summary - The company forecasts net profits of 210 million yuan, 260 million yuan, and 320 million yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 16.8%, 23.8%, and 23.6% [4][5]. - The projected revenue for 2025 is 891 million yuan, with a growth rate of 15.7% [5]. - The company's PE ratios for 2025, 2026, and 2027 are estimated at 40x, 32x, and 26x, respectively [5].

Core Insights - The company reported a revenue of 17.484 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.25%, with a net profit of 3.119 billion yuan, up 0.2% [1] - In Q3, the company achieved a revenue of 5.977 billion yuan, marking a growth of 3.83% despite a high base from the previous year [1] - The successful operation of several large ophthalmology centers indicates significant progress in the company's "1+8+N" strategy, enhancing long-term competitiveness [1] Business Structure Optimization - The company has optimized its business structure, particularly in refractive surgery, by focusing on technological upgrades, leading to a significant increase in the application of new surgical techniques [1] - The average transaction price in refractive services has increased by over 5% due to the rising proportion of new surgical techniques [1] - The anticipated approval of the ICL V5 new type of lens by the end of the year is expected to further enhance the company's business structure [1] Cataract and Vision Services - The company is adapting to changes in the market driven by reforms in medical insurance payment methods, focusing on both "popularization" and "upgrading" of cataract surgeries [2] - The volume of cataract surgeries has continued to grow, benefiting more patients, while the company is also enhancing its offerings in functional lenses and advanced surgical techniques [2] - In vision services, the company is expanding its adult eyewear services and transitioning towards "visual health management," which has shown promising results in pilot hospitals [2] Multidisciplinary Approach - The company is leveraging its comprehensive ophthalmology advantages by establishing multidisciplinary diagnostic and treatment (MDT) groups to address complex eye conditions [3] - A proactive approach has been taken to manage presbyopia by setting up specialized clinics, targeting the growing elderly population [3] Future Outlook - The company is well-positioned to meet the long-term growth in ophthalmic treatment demand due to aging populations and increasing awareness of visual health [3] - The ongoing optimization of business structure and technological upgrades are expected to provide resilience against industry fluctuations [3]